Protalix Biotherapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
AMEX
Protalix BioTherapeutics reported its financial results for the fiscal year ended December 31, 2025, highlighting a net loss and increased R&D expenses while advancing its rare disease pipeline and securing a new Elfabrio dosing approval in the EU.
AMEX
Protalix BioTherapeutics reports a profitable 2024 driven by Elfabrio and Elelyso sales, while advancing its pipeline with PRX-115 and PRX-119.
AMEX
Protalix BioTherapeutics' 10-K filing outlines the company's capital structure, stock rights, and regulatory environment, including details on its common and preferred stock, and anti-takeover provisions.